Modelling Technique, Structural Assumptions, Input Parameter Values: Which Has the Most Impact on the Results of a Cost-Effectiveness Analysis? Josephine Mauskopf Commentary 18 April 2014 Pages: 521 - 523
Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines A. T. NewallM. JitR. Hutubessy Current Opinion 03 May 2014 Pages: 525 - 531
Methods for Adjusting for Bias Due to Crossover in Oncology Trials K. Jack IshakIrina ProskorovskyJuan Valle Practical Application 05 March 2014 Pages: 533 - 546
When to Use Discrete Event Simulation (DES) for the Economic Evaluation of Health Technologies? A Review and Critique of the Costs and Benefits of DES Jonathan KarnonHossein Haji Ali Afzali Review Article 14 March 2014 Pages: 547 - 558
Cost-Effectiveness Analyses in Multiple Sclerosis: A Review of Modelling Approaches Shien GuoChristopher PelligraAnuraag Kansal Review Article 19 March 2014 Pages: 559 - 572
Cost Effectiveness of a Pharmacist-Led Information Technology Intervention for Reducing Rates of Clinically Important Errors in Medicines Management in General Practices (PINCER) Rachel A. ElliottKoen D. PutmanAnthony J. Avery Original Research Article 18 March 2014 Pages: 573 - 590
Using the EuroQol EQ-5D in Swiss Cancer Patients, Which Value Set Should be Applied? Klazien Matter-WalstraDirk KlingbielMatthias Schwenkglenks Original Research Article 27 March 2014 Pages: 591 - 599
Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation Torbjørn WisløffGunhild HagenMarianne Klemp Original Research Article Open access 09 April 2014 Pages: 601 - 612